FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280494040> ?p ?o ?g. }

• W4280494040 endingPage "155" @default.
• W4280494040 startingPage "146" @default.
• W4280494040 abstract "Targeted therapies for metastatic uveal melanoma have shown limited benefit in biomarker-unselected populations. The Treat20 Plus study prospectively evaluated the feasibility of a precision oncology strategy in routine clinical practice.Fresh biopsies were analyzed by high-throughput genomics (whole-genome, whole-exome, and RNA sequencing). A multidisciplinary molecular and immunologic tumor board (MiTB) made individualized treatment recommendations based on identified molecular aberrations, patient situation, drug, and clinical trial availability. Therapy selection was at the discretion of the treating physician. The primary endpoint was the feasibility of the precision oncology clinical program.Molecular analyses were available for 39/45 patients (87%). The MiTB provided treatment recommendations for 40/45 patients (89%), of whom 27/45 (60%) received ≥1 matched therapy. First-line matched therapies included MEK inhibitors (n = 15), MET inhibitors (n = 10), sorafenib (n = 1), and nivolumab (n = 1). The best response to first-line matched therapy was partial response in one patient (nivolumab based on tumor mutational burden), mixed response in two patients, and stable disease in 12 patients for a clinical benefit of 56%. The matched therapy population had a median progression-free survival and overall survival of 3.3 and 13.9 months, respectively. The growth modulation index with matched therapy was >1.33 in 6/17 patients (35%) with prior systemic therapy, suggesting clinical benefit.A precision oncology approach was feasible for patients with metastatic uveal melanoma, with 60% receiving a therapy matched to identify molecular aberrations. The clinical benefit after checkpoint inhibitors highlights the value of tumor mutational burden testing." @default.
• W4280494040 created "2022-05-22" @default.
• W4280494040 creator A5004526564 @default.
• W4280494040 creator A5005869236 @default.
• W4280494040 creator A5006079706 @default.
• W4280494040 creator A5011873635 @default.
• W4280494040 creator A5015836619 @default.
• W4280494040 creator A5023220573 @default.
• W4280494040 creator A5029285539 @default.
• W4280494040 creator A5031165822 @default.
• W4280494040 creator A5033334588 @default.
• W4280494040 creator A5044819986 @default.
• W4280494040 creator A5048408832 @default.
• W4280494040 creator A5053044975 @default.
• W4280494040 creator A5058109622 @default.
• W4280494040 creator A5063002725 @default.
• W4280494040 creator A5066640097 @default.
• W4280494040 creator A5071739380 @default.
• W4280494040 creator A5075632806 @default.
• W4280494040 creator A5076600698 @default.
• W4280494040 creator A5081726960 @default.
• W4280494040 creator A5085812497 @default.
• W4280494040 date "2022-07-01" @default.
• W4280494040 modified "2023-10-13" @default.
• W4280494040 title "Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study" @default.
• W4280494040 cites W1914507546 @default.
• W4280494040 cites W1975719619 @default.
• W4280494040 cites W1986664673 @default.
• W4280494040 cites W2091174084 @default.
• W4280494040 cites W2115246864 @default.
• W4280494040 cites W2194517235 @default.
• W4280494040 cites W2465860350 @default.
• W4280494040 cites W2530190674 @default.
• W4280494040 cites W2586712356 @default.
• W4280494040 cites W2590038448 @default.
• W4280494040 cites W2601520864 @default.
• W4280494040 cites W2782931979 @default.
• W4280494040 cites W2793005533 @default.
• W4280494040 cites W2799492638 @default.
• W4280494040 cites W2800413015 @default.
• W4280494040 cites W2890493993 @default.
• W4280494040 cites W2911390717 @default.
• W4280494040 cites W2920097475 @default.
• W4280494040 cites W2938206352 @default.
• W4280494040 cites W2944625512 @default.
• W4280494040 cites W2947820344 @default.
• W4280494040 cites W2953090895 @default.
• W4280494040 cites W2963842353 @default.
• W4280494040 cites W2968953400 @default.
• W4280494040 cites W2976161620 @default.
• W4280494040 cites W2976929154 @default.
• W4280494040 cites W3001646965 @default.
• W4280494040 cites W3036239157 @default.
• W4280494040 cites W3083986479 @default.
• W4280494040 cites W3085418949 @default.
• W4280494040 cites W3089562193 @default.
• W4280494040 cites W3092241364 @default.
• W4280494040 cites W3107665329 @default.
• W4280494040 cites W3109584389 @default.
• W4280494040 cites W3110376305 @default.
• W4280494040 cites W3120524959 @default.
• W4280494040 cites W3161482731 @default.
• W4280494040 cites W3167057035 @default.
• W4280494040 cites W3200574709 @default.
• W4280494040 cites W4232831292 @default.
• W4280494040 doi "https://doi.org/10.1016/j.ejca.2022.04.004" @default.
• W4280494040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35569281" @default.
• W4280494040 hasPublicationYear "2022" @default.
• W4280494040 type Work @default.
• W4280494040 citedByCount "3" @default.
• W4280494040 countsByYear W42804940402022 @default.
• W4280494040 countsByYear W42804940402023 @default.
• W4280494040 crossrefType "journal-article" @default.
• W4280494040 hasAuthorship W4280494040A5004526564 @default.
• W4280494040 hasAuthorship W4280494040A5005869236 @default.
• W4280494040 hasAuthorship W4280494040A5006079706 @default.
• W4280494040 hasAuthorship W4280494040A5011873635 @default.
• W4280494040 hasAuthorship W4280494040A5015836619 @default.
• W4280494040 hasAuthorship W4280494040A5023220573 @default.
• W4280494040 hasAuthorship W4280494040A5029285539 @default.
• W4280494040 hasAuthorship W4280494040A5031165822 @default.
• W4280494040 hasAuthorship W4280494040A5033334588 @default.
• W4280494040 hasAuthorship W4280494040A5044819986 @default.
• W4280494040 hasAuthorship W4280494040A5048408832 @default.
• W4280494040 hasAuthorship W4280494040A5053044975 @default.
• W4280494040 hasAuthorship W4280494040A5058109622 @default.
• W4280494040 hasAuthorship W4280494040A5063002725 @default.
• W4280494040 hasAuthorship W4280494040A5066640097 @default.
• W4280494040 hasAuthorship W4280494040A5071739380 @default.
• W4280494040 hasAuthorship W4280494040A5075632806 @default.
• W4280494040 hasAuthorship W4280494040A5076600698 @default.
• W4280494040 hasAuthorship W4280494040A5081726960 @default.
• W4280494040 hasAuthorship W4280494040A5085812497 @default.
• W4280494040 hasConcept C121608353 @default.
• W4280494040 hasConcept C126322002 @default.
• W4280494040 hasConcept C142724271 @default.
• W4280494040 hasConcept C143998085 @default.
• W4280494040 hasConcept C163763905 @default.

• next